Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis : Results of a pilot study. / Cai, Tommaso; Tamanini, Irene; Mattevi, Daniele; Verze, Paolo; Palmieri, Alessandro; Malossini, Gianni; Mirone, Vincenzo; Novelli, Andrea; Tascini, Carlo; Johansen, Truls E.Bjerklund.

I: International Journal of Antimicrobial Agents, Bind 56, Nr. 1, 105935, 07.2020.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Cai, T, Tamanini, I, Mattevi, D, Verze, P, Palmieri, A, Malossini, G, Mirone, V, Novelli, A, Tascini, C & Johansen, TEB 2020, 'Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study', International Journal of Antimicrobial Agents, bind 56, nr. 1, 105935. https://doi.org/10.1016/j.ijantimicag.2020.105935

APA

Cai, T., Tamanini, I., Mattevi, D., Verze, P., Palmieri, A., Malossini, G., Mirone, V., Novelli, A., Tascini, C., & Johansen, T. E. B. (2020). Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study. International Journal of Antimicrobial Agents, 56(1), [105935]. https://doi.org/10.1016/j.ijantimicag.2020.105935

CBE

Cai T, Tamanini I, Mattevi D, Verze P, Palmieri A, Malossini G, Mirone V, Novelli A, Tascini C, Johansen TEB. 2020. Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study. International Journal of Antimicrobial Agents. 56(1):Article 105935. https://doi.org/10.1016/j.ijantimicag.2020.105935

MLA

Vancouver

Cai T, Tamanini I, Mattevi D, Verze P, Palmieri A, Malossini G o.a. Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study. International Journal of Antimicrobial Agents. 2020 jul;56(1). 105935. https://doi.org/10.1016/j.ijantimicag.2020.105935

Author

Cai, Tommaso ; Tamanini, Irene ; Mattevi, Daniele ; Verze, Paolo ; Palmieri, Alessandro ; Malossini, Gianni ; Mirone, Vincenzo ; Novelli, Andrea ; Tascini, Carlo ; Johansen, Truls E.Bjerklund. / Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis : Results of a pilot study. I: International Journal of Antimicrobial Agents. 2020 ; Bind 56, Nr. 1.

Bibtex

@article{7ee8f31608954f8898315b97fb3ea04b,
title = "Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study",
abstract = "This paper presents the results of a pilot study of difficult-to-treat patients (exhibiting several previous treatment failures or detection of extended-spectrum beta-lactamase [ESBL] strains) with chronic bacterial prostatitis (CBP) who underwent treatment with fosfomycin trometamol (FT) and N-acetyl-L-cysteine (NAC). Twenty-eight patients with clinically- and microbiologically-confirmed CBP who attended a single urological institution between January 2018 and March 2019 were treated with oral administration of 3 g FT once a day for 2 days, followed by a dose of 3 g every 48 h for 2 weeks, in combination with oral administration of NAC 600 mg once a day for 2 weeks. Clinical and microbiological analyses were carried out at the time of admission (T0) and during follow-up at 1 month (T1) and 6 months (T2) after the end of treatment. Symptoms were assessed by the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and International Prostatic Symptom Score (IPSS), and quality of life was assessed by Quality of Well-Being (QoL) questionnaires. Isolated strains were Escherichia coli (23 patients), Enterococcus spp. (3 patients), and Klebsiella oxytoca (2 patients). ESBL strain was found in 19 (67.8%) patients. Microbiological eradication was documented in 21 (75%) patients at the second follow-up visit and clinical cure was achieved in 20 (71.4%) patients. Significant changes on questionnaires were recorded between baseline and follow-up visits. Fifteen of 19 patients (78.9%) with ESBL strains were cured. No significant side effects were reported. FT in combination with NAC is a promising alternative therapy in difficult-to-treat CBP patients.",
keywords = "antibiotic resistance, antibiotics, fosfomycin, N-acetyl-L-cysteine, prostatitis, urinary tract infection",
author = "Tommaso Cai and Irene Tamanini and Daniele Mattevi and Paolo Verze and Alessandro Palmieri and Gianni Malossini and Vincenzo Mirone and Andrea Novelli and Carlo Tascini and Johansen, {Truls E.Bjerklund}",
year = "2020",
month = jul,
doi = "10.1016/j.ijantimicag.2020.105935",
language = "English",
volume = "56",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier BV",
number = "1",

}

RIS

TY - JOUR

T1 - Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis

T2 - Results of a pilot study

AU - Cai, Tommaso

AU - Tamanini, Irene

AU - Mattevi, Daniele

AU - Verze, Paolo

AU - Palmieri, Alessandro

AU - Malossini, Gianni

AU - Mirone, Vincenzo

AU - Novelli, Andrea

AU - Tascini, Carlo

AU - Johansen, Truls E.Bjerklund

PY - 2020/7

Y1 - 2020/7

N2 - This paper presents the results of a pilot study of difficult-to-treat patients (exhibiting several previous treatment failures or detection of extended-spectrum beta-lactamase [ESBL] strains) with chronic bacterial prostatitis (CBP) who underwent treatment with fosfomycin trometamol (FT) and N-acetyl-L-cysteine (NAC). Twenty-eight patients with clinically- and microbiologically-confirmed CBP who attended a single urological institution between January 2018 and March 2019 were treated with oral administration of 3 g FT once a day for 2 days, followed by a dose of 3 g every 48 h for 2 weeks, in combination with oral administration of NAC 600 mg once a day for 2 weeks. Clinical and microbiological analyses were carried out at the time of admission (T0) and during follow-up at 1 month (T1) and 6 months (T2) after the end of treatment. Symptoms were assessed by the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and International Prostatic Symptom Score (IPSS), and quality of life was assessed by Quality of Well-Being (QoL) questionnaires. Isolated strains were Escherichia coli (23 patients), Enterococcus spp. (3 patients), and Klebsiella oxytoca (2 patients). ESBL strain was found in 19 (67.8%) patients. Microbiological eradication was documented in 21 (75%) patients at the second follow-up visit and clinical cure was achieved in 20 (71.4%) patients. Significant changes on questionnaires were recorded between baseline and follow-up visits. Fifteen of 19 patients (78.9%) with ESBL strains were cured. No significant side effects were reported. FT in combination with NAC is a promising alternative therapy in difficult-to-treat CBP patients.

AB - This paper presents the results of a pilot study of difficult-to-treat patients (exhibiting several previous treatment failures or detection of extended-spectrum beta-lactamase [ESBL] strains) with chronic bacterial prostatitis (CBP) who underwent treatment with fosfomycin trometamol (FT) and N-acetyl-L-cysteine (NAC). Twenty-eight patients with clinically- and microbiologically-confirmed CBP who attended a single urological institution between January 2018 and March 2019 were treated with oral administration of 3 g FT once a day for 2 days, followed by a dose of 3 g every 48 h for 2 weeks, in combination with oral administration of NAC 600 mg once a day for 2 weeks. Clinical and microbiological analyses were carried out at the time of admission (T0) and during follow-up at 1 month (T1) and 6 months (T2) after the end of treatment. Symptoms were assessed by the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and International Prostatic Symptom Score (IPSS), and quality of life was assessed by Quality of Well-Being (QoL) questionnaires. Isolated strains were Escherichia coli (23 patients), Enterococcus spp. (3 patients), and Klebsiella oxytoca (2 patients). ESBL strain was found in 19 (67.8%) patients. Microbiological eradication was documented in 21 (75%) patients at the second follow-up visit and clinical cure was achieved in 20 (71.4%) patients. Significant changes on questionnaires were recorded between baseline and follow-up visits. Fifteen of 19 patients (78.9%) with ESBL strains were cured. No significant side effects were reported. FT in combination with NAC is a promising alternative therapy in difficult-to-treat CBP patients.

KW - antibiotic resistance

KW - antibiotics

KW - fosfomycin

KW - N-acetyl-L-cysteine

KW - prostatitis

KW - urinary tract infection

UR - http://www.scopus.com/inward/record.url?scp=85085049202&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2020.105935

DO - 10.1016/j.ijantimicag.2020.105935

M3 - Journal article

C2 - 32156620

AN - SCOPUS:85085049202

VL - 56

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 1

M1 - 105935

ER -